NPM1 and acute myeloid leukemia: In the United Kingdom National Cancer Research Institute (NCRI), an AML17 study that involved 107 patients with NPM1-mutated AML receiving allogeneic HSCT, the estimated two year overall survival was 83%, 63%, and 13% in patients with negative, low (<200 copies per 105 ABL in the peripheral blood and <1000 copies in the bone marrow aspirate), and high levels of MRD respectively after a median follow-up of 4.9 years [86].